Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure | Zendy

F. Milosavljević | Zendy; N. Bukvić | Zendy; Zorana Pavlović | Zendy; Čedo Miljević | Zendy; Vesna Pešić | Zendy; Espen Molden | Zendy; Magnus IngelmanSundberg | Zendy; Stefan Leucht | Zendy; Marin M. Jukić | Zendy

Open Access

Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure

Author(s) -

F. Milosavljević,

N. Bukvić,

Zorana Pavlović,

Čedo Miljević,

Vesna Pešić,

Espen Molden,

Magnus IngelmanSundberg,

Stefan Leucht,

Marin M. Jukić

Publication year - 2020

Publication title -

jama psychiatry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.531

H-Index - 365

eISSN - 2168-6238

pISSN - 2168-622X

DOI - 10.1001/jamapsychiatry.2020.3643

Subject(s) - cyp2d6 , cyp2c19 , medicine , therapeutic drug monitoring , observational study , antipsychotic , pharmacogenetics , pharmacology , pharmacokinetics , psychiatry , genotype , schizophrenia (object oriented programming) , biology , genetics , cytochrome p450 , metabolism , gene

Precise estimation of the drug metabolism capacity for individual patients is crucial for adequate dose personalization.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research